Neuroactive Steroid Combination for Rapid MDD and PPD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants for major depressive disorder (MDD) and postpartum depression (PPD) have limited efficacy, take weeks to demonstrate full clinical effect, and are associated with undesirable side effects such as weight gain, GI symptoms, and sexual dysfunction, necessitating a need for rapid-acting therapies with reduced side effects.
Innovation Solution
A combination treatment approach involving a therapeutically effective amount of Compound (1) and an additional antidepressant, administered in specific dosages and durations, targeting treatment-naïve subjects or those without recent antidepressant use, to address MDD and PPD symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If current antidepressants (SSRI, SNRI, tricyclic antidepressants) are used to treat MDD, then they provide pharmacological treatment for depressive disorders, but they take 4 to 8 weeks to demonstrate full clinical efficacy and have limited efficacy with low remission rates
Solution Approach 1:
The patent segments the treatment approach by combining two different mechanisms of action: Compound (1) which acts as a positive allosteric modulator of GABA_A receptors for rapid symptom relief, and a second antidepressant for sustained therapeutic effect. This segmentation allows the treatment to address both the immediate need for symptom relief and the long-term need for remission.
Solution Approach 2:
The patent applies preliminary action by using Compound (1) to provide rapid symptom improvement during the latency period before the second antidepressant takes full effect. This preliminary intervention addresses the critical gap period where patients experience no relief from standard antidepressants.
2Reliability
If current antidepressants are used to treat MDD, then they provide pharmacological treatment, but they are associated with undesirable side effects including weight gain, GI symptoms, and sexual dysfunction
Solution Approach 1:
The patent uses Compound (1) as an intermediary substance that modulates GABA_A receptor activity to produce antidepressant effects through a different mechanism than traditional monoamine-based antidepressants. This intermediary approach achieves therapeutic efficacy while avoiding the side effects associated with serotonin and norepinephrine reuptake inhibition.
3Reliability
If patients wait for current standard-of-care pharmacotherapy to take full effect, then they receive appropriate treatment, but they remain symptomatic for up to 2 months during the latency period
Solution Approach 1:
The patent implements preliminary action by administering Compound (1) during the latency period to provide symptom relief before the second antidepressant achieves full therapeutic effect. This preliminary intervention eliminates the 2-month period of untreated symptoms while maintaining treatment appropriateness.
Solution Approach 2:
The patent ensures continuity of useful action by maintaining Compound (1) therapy during the period when the second antidepressant is taking effect, thereby providing continuous symptom management without interruption or gap in therapeutic benefit.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination treatment provides rapid symptom improvement during the latency phase of pharmacotherapy efficacy, reducing gastrointestinal adverse events and enhancing antidepressant efficacy.
Implementation Method 1
They are the result of a high throughput screen for positive allosteric modulators of GABAA receptors that target synaptic and extrasynaptic GABAA receptors.
Data Source
AI summary
The present disclosure relates to methods of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof with a combination of Compound (1) and an additional antidepressant, followed by continued administration of the additional antidepressant.